公开(公告)号：US20230263816A1

公开(公告)日：2023-08-24

申请号：US18005522

申请日：2021-07-16

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  TFF PHARMACEUTICALS, INC.

发明人： Robert O. WILLIAMS, III ,  Chaeho MOON ,  Sawittree SAHAKIJPIJARN ,  Dale CHRISTENSEN ,  Glenn MATTES ,  John J. KOLENG

IPC分类号： A61K31/706 ,  A61K9/00 ,  A61K47/18 ,  A61K47/26 ,  A61K47/40 ,  A61K45/06

CPC分类号： A61K31/706 ,  A61K9/0075 ,  A61K47/183 ,  A61K47/26 ,  A61K47/40 ,  A61K45/06

摘要： The present disclosure provides pharmaceutical compositions of remdesivir that may be administered by inhalation. These compositions may allow the achievement of a therapeutically effective dose of remdesivir directly to the lungs. These compositions may be used to treat one or more diseases or disorders such as a viral infection like an infection of a coronavirus.

公开(公告)号：US20220313611A1

公开(公告)日：2022-10-06

申请号：US17693062

申请日：2022-03-11

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  TFF Pharmaceuticals, Inc.

发明人： Robert O. WILLIAMS, III ,  Sawittree SAHAKIJPIJARN ,  Chaeho MOON ,  John J. KOLENG, JR.

IPC分类号： A61K9/14 ,  A61P37/02 ,  A61P31/10 ,  A61P33/10 ,  A61K9/16 ,  A61K9/50 ,  A61K31/436 ,  A61K31/506 ,  A61K31/167

摘要： In some aspects, the present disclosure provides methods of preparing pharmaceutical compositions using an suspension based thin film freezing method to obtain inhalable compositions. These compositions may have a higher homogeneity compared to compositions prepared using conventional methods. These compositions may be used to treat or prevent one or more diseases or disorders.

公开(公告)号：US20220023204A1

公开(公告)日：2022-01-27

申请号：US17235771

申请日：2021-04-20

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Hugh D.C. SMYTH ,  Hairui ZHANG ,  Zhengrong CUI ,  Jieliang WANG ,  Haiyue XU ,  Yajie ZHANG ,  Debadyuti GHOSH ,  Jasmim LEAL ,  Melissa SOTO ,  Robert O. WILLIAMS, III ,  Chaeho MOON ,  Sawittree SAHAKIJPIJARN

IPC分类号： A61K9/00 ,  A61K47/46 ,  A61K45/06

摘要： Dry powder compositions comprising biologically active polynucleotide molecules and methods for the manufacture of such dry powders are provided. In some aspects, dry powders of the embodiment comprise expressible or regulatory (e.g., siRNA) polynucleotide molecules complexed with nanoparticles. Dry powders comprising viable virus and bacteria are also provided.

公开(公告)号：US20210260150A1

公开(公告)日：2021-08-26

申请号：US17274666

申请日：2019-09-10

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  LUNG THERAPEUTICS, INC.

发明人： Robert O. WILLIAMS, III ,  Alan B. WATTS ,  Yajie ZHANG ,  Sawittree SAHAKIJPIJARN ,  Dale CHRISTENSEN ,  John J. KOLENG

IPC分类号： A61K38/08 ,  A61P11/00 ,  A61K38/10 ,  A61K9/00 ,  A61K45/06 ,  A61K9/14

摘要： Provided herein are compositions comprising caveolin-1 (Cav-1) peptides. Further provided are methods of using the Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.

公开(公告)号：US20240269225A1

公开(公告)日：2024-08-15

申请号：US18434731

申请日：2024-02-06

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  LUNG THERAPEUTICS, LLC

发明人： Robert O. WILLIAMS, III ,  Alan B. WATTS ,  Yajie ZHANG ,  Sawittree SAHAKIJPIJARN ,  Dale CHRISTENSEN ,  John J. KOLENG

IPC分类号： A61K38/08 ,  A61K9/00 ,  A61K9/14 ,  A61K38/10 ,  A61K45/06 ,  A61P11/00 ,  C07K7/06 ,  C07K7/08

CPC分类号： A61K38/08 ,  A61K9/0075 ,  A61K9/14 ,  A61K38/10 ,  A61K45/06 ,  A61P11/00 ,  C07K7/06 ,  C07K7/08 ,  C07K2319/10

摘要： Provided herein are compositions comprising caveolin-1 (Cav-1) peptides. Further provided are methods of using the Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.

公开(公告)号：US20240165045A1

公开(公告)日：2024-05-23

申请号：US18549645

申请日：2022-03-08

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Robert O. WILLIAMS, III ,  Chaeho MOON ,  Sawittree SAHAKIJPIJARN ,  Haiyue XU ,  Zhengrong CUI

IPC分类号： A61K9/51 ,  A61K39/215

CPC分类号： A61K9/5123 ,  A61K9/5192 ,  A61K39/215 ,  A61K2039/53

摘要： In some aspects, the present disclosure provides dry powder pharmaceutical compositions comprising: (A) a nucleic acid; (B) a lipid nanoparticle; wherein the nucleic acid is substantially encapsulated in the lipid nanoparticle; (C) a sugar; and (D) a pharmaceutically acceptable polymer. The dry powder composition may show improved stability relative to solution based pharmaceutical composition of nucleic acid therapeutic agents encapsulated in a lipid nanoparticle.

公开(公告)号：US20220296511A1

公开(公告)日：2022-09-22

申请号：US17698906

申请日：2022-03-18

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Robert O. WILLIAMS III ,  Jay I. PETERS ,  Tuangrat PRAPHAWATVET ,  Sawittree SAHAKIJPIJARN ,  Chaeho MOON

IPC分类号： A61K9/00 ,  A61K31/496 ,  A61K31/4412 ,  A61K31/365 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/32 ,  A61K47/40

摘要： In some aspects, the present disclosure provides pharmaceutical compositions comprising particles, wherein individual particles of the composition comprise a combination of two or more active pharmaceutical ingredients selected from: (A) nintedanib; (B) pirfenidone; and/or (C) mycophenolic acid. These compositions may be formulated for administration via inhalation. In some aspects, the present disclosure provides methods for preparing the pharmaceutical compositions of the present disclosure and methods of treating or preventing a disease or disorder using the pharmaceutical compositions of the present disclosure.